News Release excerpt provided by Dual Therapeutics .
Dual Therapeutics, LLC (“Dual Therapeutics”) today announced a strategic collaboration with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds for the treatment of cancer and other diseases.
Dual Therapeutics’ small-molecule modulators simultaneously block multiple cancer promoting pathways, particularly the growth and survival pathways, allowing a more comprehensive assault on cancer cells while sparing normal cells.
Click here to read the complete news release.
Originally published January 8, 2016.